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Human immunoglobulin E (IgE) is the most extensively glycosylated antibody isotype
so glycans attached to the seven N-glycosites (NGS) in its Fab and Fc domains
may modulate its functions. However, targeted modification of glycans in multiply
glycosylated proteins remains a challenge. Here, we applied an in vivo approach
that allows the manipulation of IgE N-glycans, using a trastuzumab equivalent IgE
(HER2-IgE) as a model. Taking advantage of plant inherent features, i.e., synthesis of
largely homogeneous complex N-glycans and susceptibility to glycan engineering, we
generated targeted glycoforms of HER2-IgE largely resembling those found in serum
IgE. Plant-derived HER2-IgE exhibited N-glycans terminating with GlcNAc, galactose or
sialic acid, lacking, or carrying core fucose and xylose. We were able to not only modulate
the five NGSs naturally decorated with complex N-glycans, but to also induce targeted
glycosylation at the usually unoccupied NGS6, thus increasing the overall glycosylation
content of HER2-IgE. Recombinant human cell-derived HER2-IgE exhibited large
N-glycan heterogeneity. All HER2-IgE variants demonstrated glycosylation-independent
binding to the target antigen and the high affinity receptor FcεRI, and subsequent similar
capacity to trigger mast cell degranulation. In contrast, binding to the low affinity receptor
CD23 (FcεRII) was modulated by the glycan profile, with increased binding to IgE variants
with glycans terminating with GlcNAc residues. Here we offer an efficient in planta
approach to generate defined glycoforms on multiply glycosylated IgE, allowing the
precise exploration of glycosylation-dependent activities.
Keywords: IgE, antibodies, glycan engineering, glycosylation, plants
INTRODUCTION
Immunoglobulin E (IgE), normally the least abundant antibody class in human
serum, is most commonly known for its role in the allergic response. The principal
mechanisms of IgE antibodies in allergic diseases are (i) recognizing allergens through
their antigen-binding regions (Fab) and (ii) interacting via their Fc regions with their
two cell surface receptors to induce the allergic cascade (Gould and Sutton, 2008).
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Both Fcε receptors and IgE are heavily glycosylated molecules,
implying a potential impact of this post-translational
modification on their activities. In fact, IgE is the most
heavily glycosylated antibody class, with seven N-glycosylation
sites (NGS) and ∼12% of their molecular weight made up
of carbohydrates (see a schematic illustration of human IgE;
Supplementary Figure 1). The glycosylation of IgE presents
peculiarities, like site-specific occupancy (lack of glycans at
NGS6) and differential site glycosylation pattern (oligomannose
vs. complex N-glycans). Serum IgE is heavily sialylated, with
significant N-glycan diversity between different (patho-)
physiological stages (Arnold et al., 2004; Plomp et al., 2014).
While N-glycans have been proven to be involved in the
modulation of IgG effector functions, relatively little is known
about their role on other antibody classes (Jefferis, 2012).
Attempts to explore IgE glycosylation have concentrated on
investigating its interaction with its two Fcε receptors, as they are
key players in the allergic cascade: the high affinity Fcε receptor I
(FcεRI), present on mast cells, basophils and eosinophils, and the
low affinity CD23 (FcεRII) found, amongst others, on B cells and
activatedmacrophages. Some studies claim that IgE glycosylation
is not essential for binding to FcεRI and subsequent Fc receptor-
mediated functions (Basu et al., 1993; Young et al., 1995;
Henry et al., 2000), while other investigations have contradicted
these results (Nettletone and Kochan, 1995; Helm et al., 1998;
Björklund et al., 1999; Hunt et al., 2005). Using deglycosylation
or genetic glycosite disruption, another study points to the
requirement of the C-terminal NGS (carrying oligomannose
N-glycans) for FcεRI binding and subsequent initiation of the
allergic cascade (Shade et al., 2015). Notwithstanding, a major
challenge to explore the role of IgE glycosylation in more
detail lies in the difficulty to produce this protein with multiple
NGS with a targeted glycosylation pattern. IgE recombinantly
produced in mammalian cell cultures exhibit a mixture of
glycoforms (Shade et al., 2015; Montero-Morales et al., 2017),
which makes a controlled manipulation difficult in this system.
In recent years, plants (and in particular the tobacco-related
species Nicotiana benthamiana) have become an interesting
platform for glycoengineering. Paradoxically, their limited
endogenous glycosylation repertoire provides an advantage for
glycoengineering, as it results in the production of homogeneous
N-glycans, with secreted proteins typically carrying only one or
two glycoforms, i.e., GnGnXF (GlcNAc2Man3XylFucGlcNAc2)
and MMXF (Man3XylFucGlcNAc2). This feature facilitates a
controlled manipulation of N-glycans. We recently developed
an engineering approach by combining stably engineered N.
benthamiana glycosylation mutants and transient expression
modules to both knock-out and knock-in targeted glycosylation
genes (recently reviewed in Montero-Morales and Steinkellner,
2018). In this context, it was shown that plants largely tolerate
human-like N-glycosylation and become capable of synthesizing
sialylated and even poly-sialylated structures (Castilho et al.,
2010; Kallolimath et al., 2016). Several human proteins have
been generated in plants with targeted N-glycosylation profiles
resembling human structures. Most of them are IgG antibodies
with only one NGS. However, engineering of proteins with
multiple NGSs is a challenge. For example, attempts to engineer
the sialylation of IgM antibodies (with five NGSs) were not
very successful, with only low amounts of sialylated forms
(24% compared to 60% in the mammalian cell-derived IgMs).
In addition, other structures usually not present on IgM, like
incompletely processed hybrid glycans, were detected (Loos et al.,
2014). Targeted engineering and detailed characterization of
glycoproteins with a glycosylation pattern as complex as IgE
antibodies has not been shown yet.
Interestingly, although not fully understood, IgE also plays a
vital role in the recognition of cancer by the immune system
and recent studies point to possible therapeutic applications of
monoclonal IgEs in the context of cancer (Karagiannis et al.,
2017; Fazekas-Singer et al., 2018). Based on their high affinity
for their FcεRI expressed on tumor-resident cells (e.g., tissue
mast cells, macrophages) and the lack of inhibitory IgE Fc
receptors (present for IgG), IgE antibodies may offer new options
over predominant therapeutic IgG molecules (Josephs et al.,
2017; Pellizzari et al., 2019). In breast cancer, comparative
studies between therapeutic IgG trastuzumab and an engineered
trastuzumab IgE antibody recognizing the tumor-antigen HER2
indicated that the IgE counterpart could complement or possibly
improve the clinical performance of trastuzumab (Karagiannis
et al., 2009).
In this study, we sought to generate IgE antibodies with
targeted glycosylation profiles and to examine their functional
activities using a trastuzumab equivalent monoclonal IgE
antibody recognizing the breast cancer antigen HER2 (HER2-
IgE) as a model. Using N. benthamiana and applying extensive
glycoengineering, we generated IgE variants with identical
protein backbones but distinct N-glycosylation patterns that
mainly differ in their core glycosylation and terminal residues,
i.e., N-acetylglucosamine (GlcNAc), galactose or sialic acid. In
addition, HER2-IgE was produced in human embryonic kidney
(Expi293F) cells (Ilieva et al., 2019) and, as observed in our
previous investigation (Montero-Morales et al., 2017), exhibited
a mixture of 30 glycoforms (most abundantly, core-fucosylated
branched glycans terminating with galactose or sialic acid). Using
ELISA and cell-based assays, we show that all recombinant IgE
variants bind to the HER2 antigen and to the high affinity FcεRI,
irrespectively of their glycosylation pattern. Accordingly, FcεRI-
dependent degranulation of mast cells is not affected by the
glycosylation status of the antibodies. In contrast, HER2-IgE
glycoforms terminating with GlcNAc residues exhibit increased
binding to the low affinity receptor CD23 when compared to
variants with a mixture of sialylated and galactosylated glycans.
We do not observe any effect of core fucosylation or xylosylation
on the tested activity assays.
MATERIALS AND METHODS
Cell Line Maintenance
The human breast adenocarcinoma cell lines SK-BR-3 (ATCC,
HTB-30) and BT-474, which naturally express the HER2 antigen,
were grown in Dulbecco’s Modified Eagle’s Medium (DMEM
GlutaMAXTM, Thermo Fischer Scientific, USA) supplemented
with 10% Fetal Calf Serum (FCS). The HER2-expressing human
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breast ductal carcinoma cell line ZR-75-30 (ATCC R© CRL-
1504TM), the rat basophilic leukemia mast cell line RBL-SX38
(Wiegand et al., 1996) expressing the human form of the
tetrameric (αβγ2) FcεRI receptor, and the lymphoblastoid B cell
line RPMI 8866, which highly expresses CD23, were grown in
Roswell Park Memorial Institute Medium (RPMI GlutaMAXTM,
Thermo Fischer Scientific) supplemented with 10% FCS. All cells
were maintained at 37◦C in 5% CO2. Human embryonic kidney
(HEK) cell-derived Expi293FTM cells (Thermo Fischer Scientific)
were grown on a Stuart orbital shaker (model SSL1), at 125 rpm
in 8% CO2 in serum-free Expi293 expression medium (Thermo
Fischer Scientific).
IgE Expression and Glycoengineering
Cloning and expression of HER2-IgE in HEK cells (Expi293FTM
expression system, HER2-IgEHEK) were described earlier (Ilieva
et al., 2019). The cloning and expression of the isotype
control chimeric NIP-IgEHEK, against the hapten 5-iodo-
4-hydroxy-3-nitrophenyl, were described earlier (Neuberger
et al., 1985). Briefly, the coding sequence of HER2-IgE
and NIP-IgE were cloned into pVitro1-hygro-mcs expression
plasmids and transiently expressed in Expi293TM cells using
the ExpiFectamineTM 293 transfection kit (Thermo Fischer
Scientific), according to the manufacturer’s instructions.
For experiments in N. benthamiana plants, the cloning
and expression of HER2-IgE (heavy and light chains) and of
the Leishmania major oligosaccharyltransferase single subunit
STT3D (LmSTT3D) were described elsewhere (Montero-
Morales et al., 2017; Castilho et al., 2018). In order to
modulate the glycosylation profile, HER2-IgE was transiently
expressed in different plant host by agro-infiltration: the wild-
type N. benthamiana, WT; the glycosylation mutant with down-
regulation of xylosyl- and fucosyltransferases, 1XTFT (Strasser
et al., 2008); the glycosylation mutant expressing a modified
human β1,4-galactosyltransferase, 1XTFTGal (Schneider et al.,
2015); and the mutant line expressing six mammalian genes
necessary for protein sialylation, 1XTFTSia (Kallolimath et al.,
2016). Agro-infiltration experiments were carried on 4–5-week-
old plants using Agrobacteria at optical density (OD600) 0.05–
0.1. Protein expression was monitored 3–5 days post-infiltration.
The procedure was recently described in detail (Loos and
Castilho, 2015). The six different IgE variants were termed
according to their host and/or glycosylation as HER2-IgEWT,
HER2-IgE1XF, HER2-IgEGal HER2-IgESia, HER2-IgEOST HER2-
IgEHEK, and NIP-IgEHEK. Notably, HER2-IgEOST refers to a
pooled sample of HER2-IgE produced in 1XTFT, 1XTFTGal,
and1XTFTSia plants.
IgE Purification
HER2-IgEHEK was purified using a HiTrap KappaSelect (GE
Healthcare, USA) pre-packed column and NIP-IgEHEK was
purified using a CaptureSelectTM LC-lambda (Hu) AffinityMatrix
(Thermo Fischer Scientific) pre-packed column. Antibodies
were eluted with 0.2M Glycine/HCl + 0.01% NaN3 (pH 2.3),
neutralized with 1M Tris (pH 9) and dialyzed against 1 × PBS
overnight. After dialysis, HER2-IgE samples were concentrated
with Amicon centrifugal filters, MWCO 10,000 kDa (Merck
Millipore, Germany).
For plant-produced HER2-IgE, 100 g of infiltrated leaves were
harvested 4 days post-infiltration, flash-frozen in liquid nitrogen
and crushed with a mortar and pestle. Total soluble proteins
were extracted in 1.5M NaCl, 45mM Tris, 1mM EDTA, and
40mM ascorbic acid for 1.5 h at 4◦C (2:1 buffer/fresh leave
weight). The extract was then centrifuged on a Sorvall R© RC 6TM
Plus Superspeed Centrifuge (Thermo Scientific) using a SLA-
1500 Rotor at 31,916 g for 20min, filtered through Miracloth
and clarified with pH precipitation (bring pH down to 5 for
5min, then bring up to 7). The supernatant was centrifuged
for 20min using an SS-34 rotor at 47,808 g, followed by
successive filtration steps through an 8–12µm filter and a
2–3µm filter. These centrifugations and filtration steps were
repeated until a clear extract was obtained. Using an ÄKTA pure
chromatography system (GE Healthcare), a Protein A column
(Protein A SepharoseTM Fast Flow, GE Healthcare) was washed
with ddH2O and equilibrated with 1 × PBS. Then, the clarified
total soluble protein was applied to the column at a flow rate
of 2 ml/min. The column was washed with 20 CV 1 × PBS
and antibodies were eluted with 0.1M Glycine/HCl (pH 2.7),
immediately neutralized with 1M Tris (pH 9) and dialyzed
against 1× PBS overnight.
All IgE antibodies were subjected to preparative size exclusion
chromatography (SEC) using aHiLoad 16/600 Superdex 200 prep
grade column (GE Healthcare) in order to separate monomeric
IgE from aggregates, degradation products, and other impurities.
The column was equilibrated with 1.5 CV running buffer (1
× PBS, 200mM NaCl, pH 7.4) before loading the sample. All
steps took place at a flow rate of 0.8 mL/min. The fractions
corresponding to the monomeric peak were collected and
concentrated with Amicon centrifugal filters,MWCO10,000 kDa
(Merck Millipore).
Size Exclusion
Chromatography—Multi-angle Light
Scattering (SEC-MALS)
HPLC-SEC combined with multi-angle light scattering (SEC-
MALS) was performed to confirm the molar mass of the
monomeric IgE resulting from preparative SEC. HPLC
(Shimadzu prominence LC20, Japan) was equipped with MALS
(WYATT Heleos Dawn8+ plus QELS; software ASTRA 6),
refractive index detector (RID-10A, Shimadzu) and a diode
array detector (SPD-M20A, Shimadzu). The column (Superdex
200 10/300 GL, GE Healthcare) was equilibrated with running
buffer (1 × PBS, 200mM NaCl, pH 7.4). Prior to analysis, the
IgE sample was centrifuged (17,000 g, 10min, 20◦C) and filtered
(0.1mm Ultrafree-MC filter, Merck Millipore). Experiments
were performed at a flow rate of 0.75mL/min at 25◦C. The proper
performance of molar mass calculation by MALS was verified by
the determination of a sample of bovine serum albumin.
Glycan Analysis
For the glycan analysis of HER2-IgE, we followed the liquid
chromatography-electrospray ionization-tandem mass
Frontiers in Bioengineering and Biotechnology | www.frontiersin.org 3 September 2019 | Volume 7 | Article 242
Montero-Morales et al. IgE Glycan Engineering
spectrometry (LC-ESI-MS/MS)-based protocol described in
Montero-Morales et al. (2017). Briefly, the heavy chain band were
excised from an SDS-PAGE, S-alkylated with iodoacetamide and
proteolytically digested with different proteases or combinations
of them to generate glycopeptides that cover all N-glycosites
(NGS): NGS1 (Asn21): NIPSNATSVTL; NGS2 (Asn49):
DTGSLNGTTM; NGS3 (Asn99): VAHTPSSTDWVDNK; NGS4
(Asn146): TINIT; NGS5 (Asn252): GTVNLTW; NGS6 (Asn264):
ASGKPVNHSTR, and NGS7 (Asn275): NGTLTVTSTLPVGTR.
NGS1 and 2 were obtained by the combined trypsin and
chymotrypsin digestion; NGS3, 5, 6, and 7 are tryptic peptides,
and NGS4 was obtained by digestion with proteinase K.
Following appropriate treatment, the peptide mixture was
analyzed using a Dionex Ultimate 3000 system directly linked
to a Q-TOF instrument (maXis 4G ETD, Bruker) equipped
with the standard ESI source (end plate offset 500V; capillary
4,500V; dry gas (nitrogen) 5.0 L/min; dry temp 200◦C) in
the positive ion, data dependent acquisition mode. MS-scans
were recorded (range: 150–2,200 m/z, spectra rate: 0.5Hz).
Instrument calibration was performed using an ESI calibration
mixture (Agilent). For peptide separation, a Thermo BioBasic
C18 separation column (5µm particle size, 150 × 0.32mm) was
used. For the relative quantification of the different glycoforms,
peak areas of EIC (Extracted Ion Chromatograms) of the first
four isotopic peaks were summed. All observed charge states
and ammonium adducts, as well as formylated glycopeptides,
were considered. MS/MS spectra were used for the verification
of the glycopeptides by detection of oxonium ions HexNAc (m/z
= 204.1), Hex+HexNAc (m/z = 366.1) and the unique Y1 ion
(peptide+HexNAc).
N-glycosylation site occupancy was calculated from the ratio
of deamidated to unmodified peptide upon N-glycan release with
0.15 mU of PNGase A (Europa Bioproducts) overnight at 37◦C.
ELISA
Medium-binding microtiter plates were coated with the
extracellular domain of HER2 (HER2-ECD, 69 kDa, produced
in-house in CHO Lec1 cells). 1µg/mL HER2-ECD was diluted
in 0.5M carbonate buffer and the plates were coated overnight at
4◦C. Control wells were coated with 1% BSA in 0.5M carbonate
buffer. The plate was washed with 200 µL 0.05% Tween-20
in 1 × PBS (washing buffer) three times, gently shaking for
5min each time. Blocking was performed with 200 µL washing
buffer supplemented with 2% BSA (blocking buffer) for 1 h
at room temperature, gently shaking. Blocking buffer was
subsequently removed and serially diluted IgE-HER2 antibody
(1:2 series dilutions, concentrations ranging between 2.44
and 5,000 ng/mL) were added on the plate, in triplicate, and
incubated for 1 h at room temperature, gently shaking. Following
three 5min washes, 100 µL of HRP-conjugated anti-human
kappa light chain antibody (A7164, Merck Millipore) diluted
1:5,000 in blocking buffer were added to each well and incubated
for 1.5 h at room temperature, gently shaking. After three 5min
washes, 100 µL HRP substrate (3,3
′
,5,5
′
-TMB, T0440 Sigma)
were added to each well and incubated for 15min in the dark.
Subsequently, 100µL 2MH2SO4 were added to stop the coloring
reaction. Absorbance was read at 450 nm, 1 s. The values from
eight BSA-coated wells as well as two HER2-ECD-coated wells
with no antibody and two HER2-ECD-coated wells incubated
with unspecific antibody were subtracted from the mean values
of the three technical repeats of each sample. Data was analyzed
on GraphPad Prism 7 and is presented as mean values with error
bar indicating the standard deviation. EC50 was calculated using
a four-parameter variable slope regression.
Flow Cytometric Evaluations of Antibody
Binding to Cell Surface Receptors
Antibody binding to the membrane-bound tumor-associated
antigen HER2 and to the FcεRI and trimeric CD23 receptors
was analyzed using a flow cytometric approach. HER2-expressing
and FcεRI-expressing adherent cells were detached using 0.25%
trypsin-EDTA, resuspended in FACS buffer (1 × PBS, 2% FCS)
(106 cells/ml) and incubated on ice with serially diluted HER2-
IgE antibody variants (1:3 dilutions, concentrations ranging
between 0.011 and 25µg/mL), or with the isotype negative
control NIP-IgEHEK (used for HER2-expressing cell lines), for
30min in 96-well round-bottom plates (100 µL, 105 cells per
well). Cells were subsequently washed with 1 × PBS (spinning
at 500 g for 5min) and incubated on ice for 20min with either
anti-heavy chain detection antibody, namely goat anti-human
IgE–fluorescein isothiocyanate (FI-3040; Vector Laboratories)
(1.5 µg antibody per well, diluted in 50 µL 1 × PBS). This was
followed by another wash with 1 × PBS and final resuspension
of the cells in 200 µL FACS buffer. The protocol was adapted for
analyzing CD23 binding on RPMI8866 cells: 5 × 104 suspension
cells were used per well (instead of 105) and were resuspended
in RPMI medium + 2% FCS in place of FACS buffer, in order
to have a higher Ca2+ concentration. The antibodies were also
diluted in RPMI medium + 2% FCS. Samples were analyzed
on a BD LSRFortessaTM (BD Biosciences, USA), using the High
Throughput Sampler (HTS) option. The results were analyzed
using FlowJo software 7.6.5. Data was analyzed on GraphPad
Prism 7. The trend line was calculated using a four-parameter
variable slope regression.
Competition Binding
IgE produced in Expi293F cells was labeled with AlexaFluor647
(Thermo Fisher Scientific) according to manufacturer’s
instructions. RPMI8866 cells were harvested and resuspended in
RPMI + 2% FBS. For every sample, 5× 104 cells were incubated
with the labeled AlexaFluor647-Expi293F IgE (25µg/mL) and
the unlabeled IgE glycovariant (0, 4, 2, 1, 0.5 times the labeled
IgE), in a final volume of 100 µL. Samples were incubated for
30min at 4◦C followed by a wash with 3mL of RPMI + 2% FBS.
Samples were resuspended in RPMI + 2% FBS and acquired at
FACS Canto II (BD Biosciences). The results were analyzed using
FlowJo software 7.6.5 and GraphPad Prism 7.
Degranulation Assays
We evaluated the ability of HER2-IgE variants to trigger
degranulation in vitro using the rat basophilic mast cell line
RBL-SX38, which expresses the human FcεRI receptor as a αβγ2
tetramer, the form naturally expressed on the surface of human
mast cells. 104 RBL-SX38 cells in 100µLDMEM+ 10% FCSwere
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plated in each well of a 96 well flat-bottomed tissue culture plate
and incubated overnight at 37◦C in a humidified CO2 incubator.
The following day, cells were sensitized with the different HER2-
IgE variants (and the isotype NIP-IgEHEK) diluted in culture
medium at 400 ng/mL, incubated for 2 h at 37◦C and washed
twice withHanks’ Balanced Salt solution (HBSS)+ 1% FCS (wash
buffer). The negative control for the sensitization step was the
incubation with medium (without HER2-IgE).
IgE crosslinking and subsequent triggering of cell
degranulation were achieved by incubating the wells for 45min
with either 100 µL of polyclonal rabbit anti-human IgE (Dako)
(final concentration: 1.5µg/mL) or HER2-expressing SK-BR-3
cells (3 × 104 cells/well) in wash buffer at 37◦C. The negative
control treatment for the degranulation step was wash buffer (no
crosslinker). The positive control for degranulation was wash
buffer+0.1% Triton-X-100 (Tx) for total degranulation.
Degranulation was terminated by placing the cells on ice and
it was measured by quantification of β-hexosaminidase release,
assayed using a fluorogenic substrate (4-methylumbelliferyl-N-
acetyl-β-D-glucosaminide) prepared according to a standard
protocol (1 mmol/L 4-methylumbelliferyl N-acetyl-b-D-
glucosaminide, 0.1% dimethyl sulfoxide, 0.1% Triton X-100, 200
mmol/L citrate, pH 4.5 (Linko-Lopponen and Makinen, 1985).
Twenty-five microliter of culture supernatant were transferred
to a FluoroNuncTM black 96 well plate and diluted with 25 µL
wash buffer. Fifty microliter fluorogenic substrate were added,
the plate was sealed and incubated at 37◦C for 2 h in the dark.
The reaction was then quenched with 100 µL/well of 0.5M
Tris pH 8.2 and the plate was read with a FLUOstar Omega
Microplate Reader (350-nm excitation and 450-nm emission;
BMG Labtech). All measurements were made in triplicate for
each condition and degranulation was normalized between
100% degranulation (treatment with 0.1% Triton-X-100 in wash
buffer) and 0% (background release from cells sensitized with
medium alone and treated with wash buffer alone).
RESULTS
Expression of HER2-IgE in Nicotiana
benthamiana and Expi293F Cells
Recently we reported the expression of an engineered
trastuzumab IgE antibody recognizing the tumor-antigen
HER2 (HER2-IgE) in Expi293F cells (HER2-IgEHEK) and in N.
benthamiana plants (Montero-Morales et al., 2017). Here, HER2-
IgE was transiently expressed in N. benthamiana with altered
genetic backgrounds: wild type, WT; 1XTFT, a glycosylation
mutant lacking the plant-specific core N-glycan residues β1,2-
xylose and α1,3-fucose (Strasser et al., 2008); 1XTFTGal, a
glycosylation mutant that elongates GnGn glycans with β1,4-
galactose (Schneider et al., 2015); and 1XTFTSia, a glycosylation
mutant for human-type sialylation (Kallolimath et al., 2016).
Additionally, to increase NGS occupancy (and induce the
glycosylation of the normally unglycosylated NGS6), we co-
expressed HER2-IgE with the STT3D oligosaccharyltransferase
(OST) from the protozoan Leishmania major in 1XTFT,
1XTFTGal and 1XTFTSia plants. OST has been used previously
to increase NGS occupancies of recombinant human proteins
expressed in plants (Castilho et al., 2018). HER2-IgE was also
produced in the Expi293TM Expression System (Thermo Fischer
Scientific), as recently described (Ilieva et al., 2019).
The different HER2-IgE variants (Supplementary Table 1)
were purified by immunoaffinity chromatography followed by
size exclusion chromatography (SEC) to isolate monomeric IgE.
HER2-IgE variants weremonitored on SDS-PAGE analysis under
FIGURE 1 | Biochemical characterization of HER2-IgE. (A) Coomassie brilliant blue stained SDS-PAGE of purified plant-produced HER2-IgE (4 µg). M, molecular
weight marker; 1, reducing conditions; 2, non-reducing conditions. Black arrowheads: heavy and light chains; gray arrowhead: assembled HER2-IgE. Molecular
weight shown in kilo Dalton (kDa). (B) Size Exclusion-HPLC measurements of HER2-IgE1XF before (gray) and after (black) preparative SEC.
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reducing and non-reducing conditions. The results show the
presence of heavy and light chains (75 and 25 kDa, respectively)
and fully assembled IgE (190 kDa, Figure 1A). Correct
assembling was further confirmed by SE-MALS (Figure 1B).
Site-Specific N-Glycosylation Occupancy
and Profiling of HER2-IgE
The heavy chain of human IgE antibodies carries seven
potential N-glycosylation sites, here numbered NGS1-7 (see
Supplementary Figure 1). First, NGS occupancy rates were
monitored by liquid chromatography-electrospray ionization-
tandem mass spectrometry (LC-ESI-MS/MS). In HER2-IgEWT,
HER2-IgE1XF, and IgE-HER2Sia, NGS1, NGS2, and NGS4 are
100% occupied; NGS3, 10%; NGS5, 55%; and NGS7, 94%
(Figure 2A; Supplementary Table 2). NGS6 is not glycosylated.
Co-expression of OST in the different plant hosts significantly
improved glycosylation of NGS3 and NGS5; this variant shows
25% occupancy at NGS3 and up to 94% at NGS5. Notably, we
obtained up to 70% glycosylation at NGS6. In HER2-IgEHEK,
NGS1, NGS2, and NGS4 are fully occupied; NGS3, NGS5, and
NGS7 exhibit 70, 91, and 97% occupancy, respectively. NGS6 is
not glycosylated. These results are in accordance with previous
investigations (Montero-Morales et al., 2017).
We have previously reported on the relative abundance
of specific N-glycans on each NGS of HER2-IgEHEK and
plant-derived HER2-IgEWT and HER2-IgE1XF (Montero-
Morales et al., 2017). In short, NGS1-5 of HER2-IgEWT
(Supplementary Figure 2, Supplementary Table 3) and HER2-
IgE1XF (Supplementary Figure 3, Supplementary Table 4)
predominantly carry a single complex N-glycan terminating
with GlcNAc with or without core-modifications, depending on
the expression host. In contrast, the HER2-IgEHEK glycosylation
profile is highly heterogeneous, with more than 30 different
complex glycans detected, most of them tri- and tetra-antennary
galactosylated or sialylated (Montero-Morales et al., 2017). In
common with serum-derived IgE, at NGS7 all recombinantly
produced HER2-IgE variants carry oligomannose glycans
(Man5-Man9, Man5GlcNAc2-Man9GlcNAc2).
While the glycosylation profiles of plant-derived HER2-
IgEWT and HER2-IgE1XF remain similar from batch to
batch, we observed differences on the glycans of HER2-
IgEHEK derived from different batches. During this study,
we compared the glycosylation profiles of two HER2-IgEHEK
batches. Core modifications (i.e., fucosylation) and antennarity
remain constant, but terminal sugar residues (i.e., galactose
and sialic acid) vary significantly (Supplementary Figure 4,
Supplementary Table 5). This is particularly pronounced at
NGS4, where the 66% galactosylated and 28% sialylated glycans
detected in batch 1 contrast with the 8% galactosylated and
85% sialylated in batch 2. Batch 1 (Supplementary Figure 5,
Supplementary Table 5) was used in functional assays.
We have also produced IgE variants with N-glycans
terminating with either with β1,4-galactose or α2,6-sialic
acid. Both glycoforms are commonly found in serum
IgEs. Our attempts to produce galactosylated HER2-IgE
(HER2-IgEGal) in the glycosylation mutant 1XTFT
Gal
resulted in heterogeneous profiles with only up to 21% bi-
galactosylated (AA) N-glycans (Gal2GlcNAc2Man3GlcNAc2)
(Supplementary Table 6). Due to its heterogeneous glycosylation
profile and batch-to-batch inconsistencies, we were not able
to generate sufficiently galactosylated HER2-IgE. Conversely,
HER2-IgESia exhibited efficiently sialylated glycans, with NaNa
(NeuAc2Gal2GlcNAc2Man3GlcNAc2) being the most abundant
FIGURE 2 | Analysis of the glycosylation status of HER2-IgE. (A) N-glycosylation site (NGS)-specific occupancy (%). Analysis of NGS1-7 of HER2-IgE expressed in
Nicotiana benthamiana wild type plants (HER2-IgEWT ), glycosylation mutants 1XTFT (HER2-IgE1XF), 1XTFT
Sia (HER2-IgESia), co-expressed with L. major STT3D
oligosaccharyltransferase (OST) in any N. benthamiana line (HER2-IgEOST ), and expressed in human Expi293F cells (HER2-IgEHEK ). The ratio of deamidated to
unmodified peptide was calculated for each NGS following N-glycan release with PNGase A treatment. N = 2, error bars show the standard deviation.
See Supplementary Table 2 for details. (B) Relative abundance (%) of glycoforms present in each occupied NGS of HER2-IgESia. For detailed information, see
Supplementary Table 7. (C) Relative abundance (%) of glycoforms present in each occupied NGS of HER2-IgEOST. For detailed information,
see Supplementary Table 8.
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glycoform. In total, glycans with terminal sialic acid range
between 45 and 78%, depending on the NGS (Figure 2B;
Supplementary Table 7). In both HER2-IgEGal and HER2-
IgESia, NGS6 is not occupied and NGS7 carries oligomannose
(74–78%) and hybrid structures (21–22%).
Upon co-expression with L. major OST, glycosylation
profiles of HER2-IgE variants show mainly complex glycans in
NGS1-5 and oligomannose structures in NGS7, independently
of their expression host (1XTFT, 1XTFTGal, or 1XTFTSia).
Furthermore, the glycans present on NGS6 follow the pattern
of NGS1-5. A pooled sample of HER2-IgE produced in
1XTFT, 1XTFTGal, and 1XTFTSia plants that exhibits
significant amounts of β1,4-galactose (over 50%) named HER2-
IgEOST (Figure 2C; Supplementary Table 8) was used for
functional assays.
HER2-IgE Antigen Binding
Fab-mediated functions were monitored by the ability of
HER2-IgE glycovariants to bind antigen, the extracellular
domain of HER2 (HER2-ECD), using an ELISA-based assay.
All plant-produced variants bind to the HER2-ECD similarly,
with EC50 values ranging between 47.3 and 62.5 ng/mL
(Supplementary Figure 6, Supplementary Table 9). HER2-
IgEHEK also binds to the HER2-ECD, although our results
point to slightly lower binding affinity (EC50 = 103.9 ng/mL)
compared to the plant-produced counterparts.
The interaction of HER2-IgE with the target antigen
was also assessed by flow cytometry. All HER2-IgE variants
recognized HER2 on three different HER2-expressing breast
cancer cell lines (ZR-75-30, SK-BR-3 and BT-474) and bound
in a dose-dependent manner, with no obvious impact of
their glycosylation profiles (Figure 3A). As expected, no
binding was observed with the hapten-specific isotype negative
control, NIP-IgEHEK.
Fc-Based HER2-IgE Activities
To examine the Fc-mediated properties of HER2-IgE we tested
the recognition of Fcε receptors (high affinity FcεRI and
low affinity CD23) on human immune effector cells by flow
cytometric measurements. Binding of HER2-IgE variants to the
high affinity receptor, FcεRI, was studied with the rat basophilic
leukemia cell line RBL-SX38, which stably expresses human
tetrameric (αβγ2) FcεRI. All the antibody variants successfully
recognized and bound to the receptor in a dose-dependent
manner. A slightly reduced binding was observed in HER2-
IgEOST and HER2-IgEHEK samples (Figure 3B).
Binding of HER2-IgE to the low affinity receptor was studied
with the human lymphoblastoid cell line RPMI8866, which stably
FIGURE 3 | Analysis of antibody target antigen and Fc receptors binding. (A) Target antigen recognition of IgE variants on HER2-overexpressing cancer cell lines. All
HER2-IgE variants bound to the target antigen in a similar dose-dependent manner in all cell lines used; the negative control (isotype NIP-IgEHEK ) does not bind. (B)
Recognition of tetrameric FcεRI on RBL-SX38 cells. All HER2-IgE variants bound to the receptor in a similar dose-dependent manner. (C) Recognition of CD23 on
RPMI8866 cells. All HER2-IgE variants bound to the receptor in a dose-dependent manner. Differences between the binding behaviors of the variants are observable
here. (D) Competition binding assay of CD23 on RPMI8866 cells. Graphs are representative of two (in some cases more) independent experiments.
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expresses CD23. As with FcεRI, all antibody variants recognized
and bound to the receptor. However, we observe an improved
binding to CD23 in variants whose glycans terminate with
GlcNAc residues (HER2-IgEWT and HER2-IgE1XF) and in those
that carry mainly galactosylated structures (HER2-IgEOST and
HER2-IgEHEK) (Figure 3C). It also should be noted that HER2-
IgEOST andHER2-IgEHEK have an overall increased glycosylation
content (Figure 2A). HER2-IgESia shows similar binding to
HER2-IgEWT at low concentrations (0.02–1.85µg/ml), but at
higher concentrations (5–50µg/ml) its binding is reduced
(Figure 3C). These binding differences were also observed in a
competition binding assay (Figure 3D).
Mast Cell Degranulation Assay
The most relevant IgE mediated biological function is the
induction of an allergic response. When immunogens crosslink
IgE-FcεRI complexes on the cell surface of mast cells, they trigger
the early phase of the allergic reaction, which involves mast-cell
degranulation: the release of pro-inflammatory mediators such
as histamine, tissue matrix-remodeling enzymes and interleukins
(Janeway et al., 2001).
Here, we tested the ability of HER2-IgE variants to induce
the degranulation of mast cells that express human FcεRI
(RBL-SX38 cells). Significant levels of degranulation were
detected upon sensitization of mast cells with HER2-IgE
followed by crosslinking with either polyclonal anti-IgE or
HER2-overexpressing SK-BR-3 breast cancer cells (Figure 4).
Sensitization with control NIP-IgEHEK followed by crosslinking
with polyclonal anti-IgE also lead to degranulation; importantly,
no degranulation was observed with NIP-IgEHEK and SK-BR-
3 cells, as NIP-IgEHEK cannot bind to and be cross-linked
by HER2-expressing cells. These data, consistent with our
findings on FcεRI binding, point to a HER2-IgE glycosylation-
independent mast cell degranulation.
DISCUSSION
In this study, we applied an efficient method for the production
of targeted glycoforms of a protein carrying multiple NGS,
exemplified by a monoclonal IgE antibody recognizing the
breast cancer antigen HER2 (HER2-IgE). HER2-IgE expressed
in human Expi293FTM cells exhibited large glycan diversity and
batch-to-batch differences, unfavorable factors when studying
glycosylation-dependent activities. We took advantage of the
limited endogenous glycosylation repertoire of plants, which
results in the synthesis of homogeneous complex N-glycans.
Combining transgenic N. benthamiana and transient expression
modules, we generate HER2-IgE antibodies glycosylated with
human-like complex N-glycans at all five NGS that naturally
carry complex N-glycans.
HER2-IgE1XF exhibits one dominant glycan, namely
GnGn (up to 80%), a structure which can be elongated to
generate glycoforms present on serum IgE, i.e., complex N-
glycans terminating with β1,4-galactose or α2,6-sialic acid.
We show the generation of efficiently sialylated HER2-IgE
using XTFTSia plants. The expression of HER2-IgE in XTFTGal
plants in order to generate galactosylated antibodies resulted in
FIGURE 4 | HER2-IgE stimulation of mast cells. IgE-mediated degranulation of
RBL-SX38 mast cells measured in negative control (no crosslinker), positive
control (polyclonal anti-IgE antibody), and using a HER2-expressing tumor cell
line to trigger cross-linking of HER2-IgE-FcεRI complexes. N = 3, error bars
show the standard deviation. ****P < 0.0001; ns, not significant. Data
representative of two independent experiments. Isotype NIP-IgE expressed in
Expi293F cells (IgE-NIPHEK ) was used as a control.
low levels of galactosylation and batch-to-batch differences,
most probably due to the presence of β-galactosidases
(Chandrasekar et al., 2014). By co-expressing OST STT3D
from Leishmania major, NGS occupancy was substantially
increased on the two sites that were inefficiently glycosylated
(NGS3 and NGS5). In addition, overexpression of OST initiated
glycosylation on NGS6, normally unglycosylated, and glycans
at this site were then processed into complex-type, similar
to NGS1-5.
IgE antibodies carry three NGSs in the Fab region, so
one could expect a link between glycosylation and antigen
binding. However, in our studies we do not observe any
substantial difference in binding of the HER2-IgE variants
to the target antigen on different HER2-overexpressing breast
cancer cell lines. Similar to IgG-FcγR interactions, IgE antibodies
mediate their pro-inflammatory properties through crosslinking
of the FcεRI—IgE complexes on the surface of effector cells
(Garman et al., 2000; Sutton et al., 2019). Our results show
glycosylation-independent binding of all HER2-IgE variants to
FcεRI expressed on the surface of mast cells. Neither terminal
sugar residues nor modification of the core sugars resulted
in obvious binding differences. Accordingly, degranulation of
mast cells, which relies on the interaction and crosslinking of
IgE and FcεRI, was not affected by the glycosylation status
of the antibodies. These results are in stark contrast to those
observed with IgG antibodies, in which binding to FcγRs and
subsequent effector functions can be modulated by the glycan
composition at the conserved single Fc NGS (Asn297) (Shields
et al., 2002; Kaneko et al., 2006; Nimmerjahn et al., 2007).
Previously it was shown that NGS7 (Asn275), the proposed
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equivalent to the single IgG Fc NGS, is crucial for FcεRI
IgE binding (Shade et al., 2015). All our IgE glycovariants
carry oligomannose structures at NGS7, so we cannot draw
conclusions from our study on the role of this NGS on the
activities of IgE.
Both IgE and IgG are able to engage a second class of
receptors, the evolutionarily related CD23 and dendritic cell-
specific intercellular adhesion molecule-3-grabbing non-integrin
(DC-SIGN), respectively, which may confer different anti-
inflammatory or immune-suppressive responses depending on
the immunological context (Anthony et al., 2008; Sutton et al.,
2019). These Fc receptors are unique among Ig receptors in
that they belong to the C-type lectin-like superfamily (Zelensky
and Gready, 2005). However, binding of IgE to CD23 is
mediated exclusively through protein–protein interactions, with
no known direct carbohydrate interaction (Dhaliwal et al.,
2012). Here, in a cell-based assay, we observed that the IgE
variants with different terminal sugars have altered CD23
affinities: glycovariants terminating with GlcNAc residues show
enhanced binding compared to variants with elongated glycans
(Figure 3C). These observations are consistent with data from
a competition binding assay, where increased galactosylation
and core modifications negatively correlate with CD23 binding
(Figure 3D). Currently the effect of terminal sialylation is
less clear, since the two samples that carry a substantial
portion of terminal sialic acids (HER2-IgESia with 44–70%
sialylated glycans and HER2-IgEHEK with 26–43%) bind to
CD23 differently, with HER2-IgESia showing significantly better
binding to CD23 than HER2-IgEHEK. This could be due
to differences in galactosylated glycans, as HER2-IgESia has
only 9–26% terminal galactose while 47–66% of HER2-IgEHEK
glycans are galactosylated. However, we cannot exclude the
possible effect of higher NGS occupancy on CD23 binding,
since HER2-IgEOST and HER2-IgEHEK have increased NGS
occupancy (on NGS3 and NGS5 and, in the case of HER2-
IgEOST, also on NGS6). In vitro studies have proposed that
glycosylation of IgG may affect its binding to DC-SIGN and
even CD23 (Sondermann et al., 2013; Yu et al., 2013). Our
results clearly point to an effect of glycosylation on IgE-CD23
binding. Nevertheless, further studies are needed to clarify
structural details.
Collectively, we demonstrate an unmatched glycan
engineering approach to generate multiply glycosylated IgE
with a targeted glycosylation pattern. Our study opens a door to
more precisely exploring of glycosylation-dependent activities,
which may be exploited for therapeutic purposes, e.g., in cancer
settings or allergic diseases.
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